Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an early eating window tame type 2 diabetes?

NCT ID NCT05015504

Disease control Sponsor: OhioHealth Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether limiting all food intake to a 10-hour window (4 AM to 4 PM) can improve blood sugar control in adults with poorly controlled type 2 diabetes. Participants will follow this eating pattern for one week while researchers track changes in average glucose, estimated A1c, insulin resistance, triglycerides, and body weight. The goal is to see if this eating schedule could help manage diabetes, possibly allowing the same or lower doses of diabetes medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Time-restricted feeding (eating only between 4 AM and 4 PM)
What this could lead to
If it works, this eating pattern could help people with type 2 diabetes better manage blood sugar, possibly with the same or even lower doses of diabetes medication.
What could go wrong
This is a small, short trial (30 people, 3 weeks), so results may not apply broadly. The early eating window may be hard to follow and could raise the risk of low blood sugar in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and \< 65 years * With the diagnosis of type 2 diabetes * A1c \>= 8.0 on the most recent test in the 3 months before enrollment * Have been on stable antidiabetics in the 3 months before enrollment * OhioHealth Patient Exclusion Criteria: * Pregnant or breastfeeding patients * Severe hypoglycemic episodes (defined as having low blood glucose levels that requires assistance from another person to treat) in the past 12 months * Unable to give informed consent * Currently enrolled in another therapeutic study * Thyroid dysfunction, as defined by abnormal thyroid function test results within the past 6 months * Advanced stage of renal (stage 4 or above) or hepatic (cirrhosis) or respiratory (needs oxygen) or heart failure (NYHA class 3 or above) * Active infection or malignancy * Dementia, or other significant mental impairment that would, in the opinion of the investigator, impede patient self-reporting * Clinician-reported history of patient non-adherence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Intermittent Fasting type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • OhioHealth Castrop Health Center

    Athens, Ohio, 45701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.